We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.
Here are some of the key takeaways from the survey:
The top two packaging needs of a biosimilar company are single supplier and low particulate specification. West can offer both of these. West works with many biosimilar companies seeking packaging recommendations, and can support your development with both containment and services offerings, de-risking your development and allowing you to maximize your time and resources to help get your drug to market quickly and safely.
West’s Ready Pack® system is a complete vial containment system that addresses the top needs of biosimilar companies. Components are supplied ready-to-use, pre-tested and proven to maintain container closure integrity, reducing the need for further processing at your site and providing assurance that the components are compatible as an integrated system. West’s Ready Pack system includes NovaPure® stoppers with tight visible particulate specification, high quality Flip-Off® CCS seals and Schott’s adaptiQ® glass vials. All components can be purchased in West’s online store, 24 hours a day. This convenience of ordering from one supplier, when it suits you, goes a long way to meeting customer expectations.”
The West team understands the unique challenges of biosimilar development and can assist customers with a variety of solutions, designed to help move products to market faster and more efficiently.
It is vitally important for the unique needs of a company developing a biosimilar drug to have solutions available, because developing a biosimilar is as complex as developing a biologic drug, if not more so. As more biosimilars are approved and enter the market, they will continue to grow in importance, bringing greater access to affordable treatment options. A critical success factor for the least risky journey to market relates to the choice of partners along the way. By choosing a partner, such as West, who understands what you need and when you need it will position you to mitigate known risks as early as possible, thereby minimizing risk downstream.
This survey helped confirm to us that we understand the specific needs of a company developing a biosimilar and we are here to help get your treatment to patients faster and more efficiently.
Learn more about the Ready Pack system and West Services here. Please contact our Technical Customer Service team for additional information and if you have any questions.
Ready Pack, NovaPure, and Flip-Off are trademarks and registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. adaptiQ is a registered trademark of Schott AG.
A European Customer Satisfaction Study conducted in 2012 offered West customers a chance to be heard, and provided a contribution to the José Carreras Leukämie-Stiftung (José Carreras Leukemia Foundation) based in Munich, Germany. The EU-wide study was conducted as an online survey and ran throughout the summer. To encourage customer participation, West made a charitable contribution for each completed survey. Thanks to a high level of customer participation (customers from 28 countries provided feedback), West was able to generate €2,260 (more than $3,000) for the charity.
In the latest installment of our video series, West on the Road, we travel across the Atlantic to our manufacturing facility in Eschweiler, Germany. There we meet Manager of Process Engineering Martin Rothstein, who says he’s impressed at how often he has encountered West products in his private life, whether visiting a family member in the hospital or during a vaccination appointment for one of his two small children.
Lyophilization is widely used for pharmaceuticals to help preserve parenteral drugs that are unstable in liquid formulation, particularly biologics. Lyophilized drugs have many advantages like prolonged shelf life, easy dissolution and good stability. However, a suitable container closure system is necessary to ensure the successful lyophilization of pharmaceutical products while maintaining product quality.
The West without Borders fundraising initiative had a terrific year in 2011 and as we kick off the 2012 campaign, we can look forward to another great year of aiding charities in the communities where West employees live and work. In 2011, West employees contributed more than $210,000 to aid local charities.
The Food and Drug Administration (FDA) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2019. The Federal Food, Drug and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2017 (MDUFA IV), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2019, which apply from October 1, 2018, through September 30, 2019.<br />
English
Chinese
